


CalRegen, Inc
870 United Nations Plaza, Suite 13G
New York, NY 10017

Leslie I Gold, PhD
T 917-855-7809, F 212-223-3961
www.calregeninc.com
Email: Leslie.gold@nyumc.org



CalRegen Inc

Industry:

**Biotech
Life Science**

Management:

Executive Leadership

- Leslie I Gold, PhD, Founder, CSO
- Glenn Cornett, MD, PhD, CEO
- Board
- Aron Wahrman, MD, MBA, MHCDS, FACS
- Mark P Solomon, MD
- Marek Michalak, PhD, Founder
- Eric Hermann, Chair, Founder
- Dennis Hranitzky, JD, Dechert, LLP

Scientific Advisory Board

- Elma Hawkins, PhD, Advisor
- Seeking KOLs and biotech experts

Number of Employees: 2

Finance:

- Seeking Auditor

Current Investors:

- \$1M Charles Cahn of CahnMedtech;
- \$500K Eric Hermann, FH International Emerging Markets Fund,
- \$200K John P Spain,
- \$100K US Army MEDCOM,
- \$250K NYU School Medicine, OIL.
- \$3M Eric Hermann, Dennis Hranitzky

Amount of Financing Sought:

- \$20-30 M for Phase II for 2nd generation 1st in class collagen and elastin-inducing dermal filler

Legal:

Corporate

- Faith Charles, JD, Thompson Hine LLP

IP

- Irina Vainberg, PhD, JD, Troutman and Sanders, LLP

Executive Summary:

CalRegen is commercializing calreticulin (CRT) as a biotherapeutic **that has unique tissue regenerative-inducing properties not previously shown for any agent or matrix scaffold.** CRT treatments include cosmetic soft tissue augmentation, new hair follicle induction, and topical treatment of chronic cutaneous wounds, burn wounds, and ophthalmic ulcers.

Company History: Founded in 2010, based on the discovery that topical application of CRT to porcine (heal similar humans) and diabetic impaired mouse wounds markedly enhanced wound healing. Wounds regenerated replete with epidermal appendages (pigmented hair, sebaceous glands) and no scar. CRT by far exceeded Regranex (only topical available, not effective) in treatment of porcine wounds. 3 publications¹.

Market Opportunities / Unmet Needs:

CRT use is a **paradigm shift by regenerating tissue rather than healing wounds;** no new treatment in 20 yrs.

- 1. Need:** improve longevity of dermal fillers. First in class cosmetic dermal filler for inducing one's own collagen, elastin, and fibronectin scaffold, US \$2.5Bn, CAGR=14%
- 2. Need:** hair loss/balding, CRT induces new hair follicle growth, US \$2.8 Bn.
- 3. Need:** Non-healing diabetic foot ulcers DFUs; US=3.8 mil, Global=30 mil. Other chronic wounds Total >8 mil US; 44 mil Global, Market: \$25Bn, CAGR=26%.

Products/Services – Launched & Pipeline: First cosmetic use of CRT for soft tissue augmentation. Human POC data Phase Ib/IIa complete by June-Dec '19.

Commercial / Technical Milestones: Human recombinant CRT scaled-up to 1.8 g/L (Syngene Int'l, India). GMP CRT=approx. \$2,500/gram. **Technical milestones completed:** in vitro and in vivo POP data for all indications, CMC completed.

Intellectual Property: Issued: CRT treatment of chronic wounds, US 8/2015. Treatment of fine lines and wrinkles, US 2/2016; EPO 4/2017. Cosmetic method for de novo growth of epidermal appendages, EPO, approved 2018. Pending: CRT Therapeutic and cosmetic uses (other indications).

Competition: **1. Cosmetic use:** > 6 dermal fillers and Botox. No bioactive class of dermal filler. **2. Hair regrowth.** No effective product exists. **3. DFU,** Regranex[®], >75 times more expensive than CRT. Acellular and cellular devices/matrices expensive, difficult to store & use. None regenerate tissue.

Financial Projections (Unaudited): Recent capital raise: \$3M for PK/PD/Tox, file IND, Phase Ib/IIa for CRT bioactive dermal filler.

Purpose of Presentation: Investment/Partnership, Product Development